Welcome to our dedicated page for NUGEN MEDICAL DEVICES news (Ticker: NGMDF), a resource for investors and traders seeking the latest updates and insights on NUGEN MEDICAL DEVICES stock.
NuGen Medical Devices Inc. develops needle-free devices for subcutaneous drug delivery, centered on the InsuJet™ system for insulin administration and related consumables. Company news commonly covers commercialization of InsuJet and EziAutoJector® through distributors and pharmacy channels, product availability in markets such as France and the United Kingdom, and medical-device regulatory updates tied to national approvals and licensing.
NuGen updates also include research and development for prefilled and cartridge-based needle-free injection formats, patent activity for Ready-to-Fill COP/COC nozzles and the Prefilled Nozzle platform, annual financial results, and governance changes involving financial reporting functions.
NuGen Medical Devices (OTC:NGMDF) filed a patent application for a Ready-to-Fill COP/COC needle-free injection nozzle that integrates with a reusable auto-injector as a Prefilled Nozzle (PFN) platform. The nozzle targets high-pressure jet injection, 0.5 mL and 1.0 mL formats, and is developed with Gerresheimer to fit existing aseptic fill-finish lines.
Key near-term milestones include sample qualification for preclinical testing by end-2026 and a fixed-dose auto-injector launch planned for 2027.
NuGen Medical Devices (TSXV:NGMDF) temporarily halted sales of certain devices in Canada after its Health Canada licence expired due to an untimely certificate renewal. This lapse is not a regulatory suspension or safety issue. A new licence application has been submitted and the company says communications with Health Canada are ongoing; global operations remain unaffected.
NuGen Medical Devices (TSXV: NGMDF) announced a change in senior finance leadership effective January 31, 2026. Veronique Laberge resigned as Chief Financial Officer and Corporate Secretary and Ajay Mishra was appointed to both roles. The company said Mr. Mishra will assume responsibility for financial reporting and related functions.
NuGen Medical Devices (TSXV: NGMDF) provided a 2025 year-end update outlining R&D, technical, clinical, and commercial progress across its needle-free subcutaneous drug-delivery programs.
Key 2025 achievements include feasibility of a Ready-to-Fill Nozzle, advancement of a next-generation variable-dose jet injector, pressure-profile optimization, prototype progress on a patented refill cartridge system, and development of an animal-use PetJet injector.
Operational expansions included a Netherlands design hub, two MedTech hires in China, clinical team growth in France, Brazil and Malaysia, formation of a Medical Advisory Board, UK launch of the EZIAUTOJECTOR with NHS Drug Tariff approval, and ongoing distributor and payer engagement in Mexico, Asia and Canada.
NuGen Medical Devices (TSXV: NGMD) has achieved a significant milestone as its UK distribution partner, EziAutoJector Ltd, received NHS Drug Tariff approval for its needle-free insulin delivery device. This approval means UK diabetes patients can receive the EziAutoJector device and accessories at no cost through NHS-funded care.
The company has established distribution channels through a major pharmaceutical wholesaler for both high-street and online pharmacies. The initiative includes educational programs targeting healthcare professionals and a direct-to-consumer e-commerce channel. Notably, each patient switching to EziAutoJector eliminates over 1,000 single-use insulin needles annually, supporting NHS environmental and cost-efficiency goals.
NuGen Medical Devices (TSXV: NGMD) has announced the development of a next-generation needle-free injection system featuring innovative internal cartridge technology. The system, protected under international patent WO2021206553, integrates a sterile internal insulin cartridge into their proprietary autoinjector.
The new design eliminates the need for external connectors and manual filling, offering improved safety and ease of use compared to current systems like InsuJet. Key technical features include an internal cartridge integration, backflow control mechanism, and enhanced usability.
Under CEO Liang Lin's leadership, NuGen plans to begin clinical investigations using their current platform while developing the new system. The company aims to produce working prototypes within six months and begin tooling investment in early 2026.
NuGen Medical Devices (TSXV: NGMD) has launched a French e-commerce platform www.insujet.fr for its needle-free insulin delivery device InsuJet. Developed with Sol-Millennium France, the platform offers product information, educational resources, and secure purchasing with optional nurse-led onboarding support.
The launch addresses a significant market opportunity in France, where 4.33 million people (6.3% of the population) lived with diabetes in 2022. Diabetes-related reimbursements in France increased from €7.6 billion in 2015 to over €10 billion in 2022. With 92% of Type 2 diabetes patients delaying insulin start due to needle anxiety, InsuJet aims to improve treatment adoption and reduce healthcare costs.
NuGen Medical Devices reported impressive financial results for 2024, marking a significant milestone in its commercial expansion. The company, known for needle-free therapeutic administration devices, achieved a remarkable 305% revenue increase and a 317% rise in gross profit.
Key financial highlights include a 31% reduction in selling, general and administrative expenses, and a 36% decrease in operational losses. The company successfully improved its balance sheet through debt renegotiation and secured a $10 million convertible debentures private placement in Q3. Working capital improved significantly to $6,466,218, compared to a negative $1,960,731 in 2023.
The company's InsuJet™ sales contributed to this record-breaking year, with Q4 shipments fulfilling previously announced orders. Management expects continued growth in 2025, focusing on expansion in Canada and Europe while investing in product development to enhance patient care outcomes.
NuGen Medical Devices (TSXV: NGMD) announces expanded distribution of its InsuJet™ needle-free insulin delivery device across Canada following Health Canada approval and nationwide introduction in November 2024.
The device is now available through major pharmacy retailers including London Drugs, Pattison Food Group, Pure Integrative Pharmacies, Imperial Distributors, Shoppers Drug Mart, and McKesson Canada. New partnerships with Kohl & Frisch and a national retail partner will begin mid-April 2025.
The company's Canadian distributor, Sol-Millennium, has partnered with MyRxCare and Greenshield Canada for pharmacy adjudication and educational support. Additionally, they continue collaboration with I Challenge Diabetes, whose CEO Chris Jarvis promotes the technology nationwide. Sol-Millennium is actively participating in various healthcare conferences throughout 2025 to engage with healthcare professionals and promote the benefits of InsuJet™.
NuGen Medical Devices has appointed Liang Lin as its new Chief Executive Officer. Lin, who joined NuGen's board in September 2024 following Sol-Millennium Medical Group's (SolM) strategic investment, brings extensive experience in the medical device sector. As the founder and CEO of SolM, Lin has demonstrated success in expanding international operations, particularly in North America and Brazil through strategic acquisitions.
Under Lin's leadership, SolM has established offices across Europe and the Middle East, invested in R&D facilities in Asia and Europe, and developed innovative medical devices. Lin replaces Karen Dunlap, who served as Interim CEO and will continue with the company as director and Chief Customer Officer. In his new role, Lin aims to leverage his industry expertise to drive global sales growth and meet anticipated InsuJet™ production demands for 2025.